The New Age Health Sciences Division leverages its extensive IP portfolio & clinical expertise to develop, market, and distribute a portfolio of research-driven products that address relevant health issues for consumers globally.

The portfolio of brands and IP in New Age's Health Sciences Division addresses everyday fundamental human need-states and bridges the divide between pharmaceuticals and nutraceuticals - delivered in a highly efficacious supplement form.

’NHANCED Cell Defense

Developed by the New Age Health Sciences Division, 'NHANCED Cell Defense is a daily micronutrient supplement designed to protect and shield the body's cells, and help sustain and protect their healthy structure and function.

The body's cells are under attack every day by toxic environmental exposure, and 'NHANCED Cell Defense helps maintain cells' proper health. 

Its formula is patent-pending, and this product was studied in collaboration with the United States Department of Defense and NASA.   

 

Daily micronutrient supplement designed to protect and shield the body’s cells

Nutrition Facts

Serving Size: 4 capsules
Servings per Container: 30
Amount Per Serving % Daily Value
Vitamin A (as Beta Carotene & Retinyl Palmitate) 5500 IU 183%
Vitamin C (as Ascorbic Acid) 250 mg 278%
Vitamin D (as Cholecalciferol) 200 IU 25%
Vitamin E (as D-Alpha Tocopherol & D-Alpha Tocopheryl Acetate) 200 IU 935%
Thiamin (as Thiamin Mononitrate) 4mg 333%
Riboflavin 5mg 385%
Niacin (as Niacinamide) 30mg 188%
Vitamin B6 (as Pyridoxine HCL) 5mg 294%
Folic Acid 200 mcg 50%
Vitamin B12 (as Cyanocobalamin) 10 mcg 417%
Biotin 200 mcg 667%
Pantothenic Acid (as Calcium D-Pantothenate) 10 mg 200%
Calcium (from Coral Calcium) 60 mg 5%
Magnesium (as Magnesium Oxide) 100 mg 24%
Zinc (as Zinc Gluconate) 15 mg 136%
Selenium (as Selenium Yeast) 200 mcg 364%
Chromium (as Chromium Yeast) 50 mcg 143%

PROPRIETARY BLEND: 310 mg* L-cystine, Alpha Lipoic Acid, & Coenzyme Q10
*Daily Value (DV not established


OTHER INGREDIENTS

Hydroxypropyl Methylcellulose (Vegetable Capsule), Microcrystalline Cellulose, Modified Food Starch, Silicon Dioxide, Magnesium Stearate.

ABOUT

New Age's Health Sciences intellectual property encompasses 11 major patents, and cooperative research studies and human trials done with some of the most prestigious and respected institutions in the world.

New Age's IP portfolio features patents & scientific research addressing major consumer opportunities, including: electrolyte replacement, neurological protection and improvement, cardiovascular health, radiation protection, diabetes treatment, hearing health, and digestive health. The Division intends to continue launching new products into market on a yearly basis, satisfying a broad set of consumer need-states with cutting-edge, clinical-grade solutions.

Our Team

Randy L. Looper | President of New Age Health Sciences Divisions

Randy is a Senior Business Executive with an exceptional performance record in sales, marketing and strategic planning. After spending 23 years in the pharmaceutical industry, he decided to take his experience to the small business and entrepreneurial world where he has led commercial expansion in existing companies, and started new companies from concept to execution with innovative, science-based products. His impressive career spans several Fortune 500 companies such as Monsanto/G.D.Searle, Upjohn/Pharmacia and Pfizer Inc. Randy has developed a broad expertise as an Executive Leader in the Healthcare field, and has since moved on to run the Health Sciences Division with a desire to provide healthier & more clinically effective products, without dangerous side effects. His strong science background, combined with his ability to translate patents & research into marketable products forged a successful path in both the pharmaceutical and nutraceutical industries.

In his career, Randy was actively involved in some of the most successful ‘first to market” product launches in pharmaceutical history, such as Ambien and Celebrex, serving in both a marketing & sales capacity for these multibillion-dollar products. At the request of the President of Pharmacia, Randy developed and built the Specialty Sales Divisions in Urology, Neurology, Orthopedics and Rheumatology medical channels. With experience leading divisions with over 300 personnel & delivering over 700 million dollars of annual sales, he’s earned top performance awards at each company throughout his career.

In his last role as President and CEO of Premier Micronutrient Corporation (PMC), the company experienced steady sales growth as he built the framework to launch 4 consumer verticals that included over 18 different nutritional health products. At PMC, he led the transition from a government-based R&D facility to an expansive international commercial footprint. The increase in commercialized growth culminated in the sale of PMC to New Age Beverages Corporation in May of 2017. Randy is currently serving as the President of the Health Sciences Division at New Age, with the goal of leveraging PMC’s proven science portfolio into healthy functional beverages for the consumer market.

In addition to his Board of Directors responsibilities for PMC, Randy has also served on several Boards and committees involving NFL Cardiovascular and Neurologic safety. This has aligned with his personal interest to help find solutions to unmet medical needs involving Military, First Responders and Professional Athletes.

Gerald M. Haase, M.D. | Chief Medical Officer

Gerald M. Haase is Clinical Professor of Surgery at the University of Colorado, School of Medicine and principal of Rocky Mountain Medical Research. He was co-founder of Premier Micronutrient Corporation, a nutritional science research and development entity that was acquired by public company, New Age Beverages, of which he became Chief Medical Officer. He is the co-founder of CURE, a non-profit foundation assisting China in management of cancer in children. Dr. Haase has been actively involved in medical research and clinical trials for 35 years including the design of central venous access devices, applications for intra-operative radiation therapy in pediatric solid tumors, technical surgical innovations in adult and childhood cancer, and development of novel strategies for antioxidant micronutrient therapy for war fighter protection, adverse clinical conditions, against hazardous exposures and for optimal health.

Dr. Haase received his undergraduate degree from the Johns Hopkins University and M.D. degree from Tufts University School of Medicine with graduate honors in research. His surgical training was at the University of Colorado, Health Sciences Center and he specialized in pediatric surgery and oncology at Children’s Hospital Medical Center, Boston, and Nationwide Children’s Hospital, Columbus, Ohio. He received U-10 grant funding from the National Institutes of Health cooperative group clinical trials program and U.S. Congressional funding for Cooperative Research and Development Agreements with the Department of Defense and NASA. He has held certification and re-certification from the American Board of Surgery in General Surgery, Pediatric Surgery and Critical Care.

Academically, he was chairman of the Department of Pediatric Surgery at Children’s Hospital Colorado and consultant pediatric surgeon to the Department of the Army at Fitzsimmons Medical Center. Dr. Haase was chairman of the Cancer Committee of the American Pediatric Surgical Association, and vice-chairman of the Children’s Cancer Group, a cooperative research consortium of the National Cancer Institute. He was a member of the National Board of Directors of the American Cancer Society, chairman of its Task Force on Children and Cancer, a member of its Medical Affairs Committee and its representative to the Alliance for Childhood Cancer. He was also a member of the National Wilms Tumor Study Group.

Dr. Haase also served as chairman of the Board of Scientific Counselors of the Cancer Treatment Research Foundation and as a senior member of the Commission on Cancer of the American College of Surgeons. He was appointed to the Board of Trustees of the National Childhood Cancer Foundation and served on its Medical and Scientific Advisory Board. Dr. Haase has published 180 scientific papers, is the inventor or co-inventor of ten issued U.S. patents for micronutrient and phytonutrient therapy with five pending patents and been the recipient of clinical research grants and contracts funded at a several million-dollar cumulative level.

He has been an editorial reviewer for numerous journals including The Journal of Pediatric Surgery, Cancer, and The American Journal of Diseases of Children and was a member of the editorial board of The Annals of Surgical Oncology. Dr. Haase participates with the International Office of the National Cancer Institute and has been an examiner in pediatric surgery for the American Board of Surgery. He is a member of more than 25 professional societies including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences, American College of Physician Executives, and is a charter member of the International Society of Pediatric Surgical Oncology. In addition, he served on the Board of Directors of the Pacific Association of Pediatric Surgeons.

Reginald Kapteyn, D.O. | New Age Board of Directors

Reginald Kapteyn, D.O. is currently Director of Vivitris Life Sciences in Spring Lake, Michigan, and is a practicing private practitioner at Orthopedic Associates Muskegon. He also serves as a medical consultant for Hydrocision Inc., where he has helped to develop a novel, minimally invasive high-pressured microwater jet for surgical debridement of chronic tendon injuries. He currently is principal investigator for a Western IRB approved study utilizing the TenJet hydrotenotomy device for chronic medial and lateral elbow pain. He is board certified in physical medicine and rehabilitation. Kapetyn served as an Interventional Pain Fellow at the University of Wisconsin, in the Department of Orthopedics & Rehabilitation. Dr. Kapteyn was also a clinical instructor for the UW School of Medicine, with focused training for interventional spine management.

After his fellowship at the University of Wisconsin, Kapteyn accepted a faculty position at the University of Cincinnati, serving as Medical Director at Drake Hospital, an affiliate hospital with University of Cincinnati Physicians. This includes serving as the Director of inpatient and outpatient pain management, including surgical implantation of neurostimulators, pain pumps, kyphoplasty, endoscopic lumbar decompression, and percutaneous tenotomies. While there he also served as President of the Medical Executive Committee, also serving as an acting member of the drug planning and development committee at University of Cincinnati Hospital. Dr. Kapteyn has expertise in developing cutting edge efficacious, minimally invasive medical devices with full 510K FDA approval for rapid implementation into standard of care practice with distribution channels. Principle investigator on numerous current IRB peer reviewed studies, so that efficacy is established concurrently with device development.

Dr. Kapteyn completed his residency training at Georgetown University Hospital, and his research fellowship was performed at the National Institutes of Health in Bethesda, Maryland where he was a published author. He completed his surgical fellowship training in sports and spine medicine at the University of Wisconsin. Dr. Kapteyn obtained his Doctorate in Osteopathic Medicine from the West Virginia School of Osteopathic Medicine.